ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody? Platform for Three Bispecific Antibody Programs
Wuxi Biologics
September 27, 2018WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody? Platform to develop three bispecific antibodies. -
I-Mab Biopharma, MorphoSys declares China IND Submission of monoclonal antibody
biospectrumasia
August 10, 2018The company has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma. -
I-Mab Biopharma, ABL Bio collaborate for innovative bispecific Abs
biospectrumasia
July 30, 2018Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment.
Pharma Sources Insight January 2025
